Zheng Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zheng Wu has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Zheng Wang
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
18 shared publicationsShuai Wu
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
12 shared publicationsLiang Han
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
10 shared publicationsCancan Zhou
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
8 shared publicationsJiaqiang Ren
Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University
8 shared publicationsFan Chen
Department of Hepatobiliary Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China
7 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1943757
Clinical and imaging differentiation of intrapancreatic accessory spleen from pancreatic neuroendocrine tumor and solid-pseudopapillary tumor: a retrospective analysis
Background: Intrapancreatic accessory spleen (IPAS) represents a rare anatomical variant of the spleen that is misdiagnosed as pancreatic neoplastic lesions. Notably, IPAS is often erroneously identified as pancreatic neuroendocrine tumor (PNET) or solid pseudopapillary tumor (SPT), which consequently results in unnecessary resection of the pancreas. This study aimed to summarize the clinical, imaging and laboratory characteristics of these lesions, clarify the key differential diagnostic points among them, and thereby enhance the clinical understanding and preoperative diagnostic accuracy of IPAS. Methods: This retrospective study analyzed all 7 cases of IPAS diagnosed at our hospital from January 2008 to December 2025. For comparative analysis, consecutive patients with pathologically confirmed PNET ( n = 18) and SPT ( n = 21) treated at the same institution between January 2023 and June 2025 were included. Clinical, imaging and pathologic characteristics were compared descriptively. Key points of differential diagnosis were summarized. Results: IPAS was distinguished from PNET and SPT primarily by consistent location in the pancreatic tail (100%), frequent heterogeneous arterial-phase enhancement with CT attenuation often similar to the spleen, universal adjacency to the splenic vessels, solid consistency, and predominantly reddish-brown gross appearance, with most lesions showing a soft texture. In contrast, PNET and SPT showed more variable location, enhancement patterns, attenuation relative to spleen, vessel contact rates, and pathologic color/texture. SPTs are typically larger and more frequently exhibit calcification. Conclusion: For lesions located in the pancreatic tail, adjacent to the spleen, and exhibiting heterogeneous enhancement in the arterial phase, the possibility of IPAS should be thoroughly considered. Nevertheless, surgical resection remains rational and appropriate when preoperative evaluation cannot completely exclude the possibility of PNET, SPT, or other pancreatic lesions.
- 23 September 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1943757
Open AccessClinical and imaging differentiation of intrapancreatic accessory spleen from pancreatic neuroendocrine tumor and solid-pseudopapillary tumor: a retrospective analysis
Background: Intrapancreatic accessory spleen (IPAS) represents a rare anatomical variant of the spleen that is misdiagnosed as pancreatic neoplastic lesions. Notably, IPAS is often erroneously identified as pancreatic neuroendocrine tumor (PNET) or solid pseudopapillary tumor (SPT), which consequently results in unnecessary resection of the pancreas. This study aimed to summarize the clinical, imaging and laboratory characteristics of these lesions, clarify the key differential diagnostic points among them, and thereby enhance the clinical understanding and preoperative diagnostic accuracy of IPAS. Methods: This retrospective study analyzed all 7 cases of IPAS diagnosed at our hospital from January 2008 to December 2025. For comparative analysis, consecutive patients with pathologically confirmed PNET ( n = 18) and SPT ( n = 21) treated at the same institution between January 2023 and June 2025 were included. Clinical, imaging and pathologic characteristics were compared descriptively. Key points of differential diagnosis were summarized. Results: IPAS was distinguished from PNET and SPT primarily by consistent location in the pancreatic tail (100%), frequent heterogeneous arterial-phase enhancement with CT attenuation often similar to the spleen, universal adjacency to the splenic vessels, solid consistency, and predominantly reddish-brown gross appearance, with most lesions showing a soft texture. In contrast, PNET and SPT showed more variable location, enhancement patterns, attenuation relative to spleen, vessel contact rates, and pathologic color/texture. SPTs are typically larger and more frequently exhibit calcification. Conclusion: For lesions located in the pancreatic tail, adjacent to the spleen, and exhibiting heterogeneous enhancement in the arterial phase, the possibility of IPAS should be thoroughly considered. Nevertheless, surgical resection remains rational and appropriate when preoperative evaluation cannot completely exclude the possibility of PNET, SPT, or other pancreatic lesions.
- 24 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 880
Short-term outcomes of robotic-assisted versus open Frey procedure in chronic pancreatitis: a single-center retrospective cohort study
Early surgery is increasingly recommended for chronic pancreatitis (CP) who meet surgical criteria. The Frey procedure is widely performed, but evidence regarding robotic Frey (R-Frey) remains limited due to the technical challenges posed by pancreatic inflammation and adhesions. This retrospective study included consecutive CP patients who underwent Frey surgery at a single center between January 2016 and May 2025. Primary outcomes were postoperative major complications (PMC; Clavien-Dindo ≥IIIa) and short-term pain relief. A 1:1 propensity score matching (PSM) was performed to reduce baseline imbalance. Among 81 patients included (34 R-Frey, 47 O-Frey), PSM yielded 25 matched pairs. In the overall cohort, no significant differences were observed in PMC (P = 0.270), or the proportion of patients achieving ≥ 50% VAS reduction (P = 0.647). R-Frey was associated with longer operative time (P = 0.013), shorter hospital stay (P = 0.035) and lower ICU stay rate (P = 0.050). After PSM, differences in hospital stay (P = 0.520) and ICU stay (P = 0.185) were no longer significant, while no significant differences were observed in complication rates or pain relief. R-Frey was performed in a selected cohort with more favorable baseline characteristics. After PSM, no significant differences in safety outcomes were detected, although the study was underpowered to establish non-inferiority. The initially observed advantages in hospital stay and ICU stay disappeared after matching, suggesting that they may influenced by patient selection rather than the surgical approach. These findings suggest that R-Frey is partly feasible in carefully selected CP patients, though larger studies are needed to confirm safety equivalence.
- 24 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 880
Short-term outcomes of robotic-assisted versus open Frey procedure in chronic pancreatitis: a single-center retrospective cohort study
Early surgery is increasingly recommended for chronic pancreatitis (CP) who meet surgical criteria. The Frey procedure is widely performed, but evidence regarding robotic Frey (R-Frey) remains limited due to the technical challenges posed by pancreatic inflammation and adhesions. This retrospective study included consecutive CP patients who underwent Frey surgery at a single center between January 2016 and May 2025. Primary outcomes were postoperative major complications (PMC; Clavien-Dindo ≥IIIa) and short-term pain relief. A 1:1 propensity score matching (PSM) was performed to reduce baseline imbalance. Among 81 patients included (34 R-Frey, 47 O-Frey), PSM yielded 25 matched pairs. In the overall cohort, no significant differences were observed in PMC (P = 0.270), or the proportion of patients achieving ≥ 50% VAS reduction (P = 0.647). R-Frey was associated with longer operative time (P = 0.013), shorter hospital stay (P = 0.035) and lower ICU stay rate (P = 0.050). After PSM, differences in hospital stay (P = 0.520) and ICU stay (P = 0.185) were no longer significant, while no significant differences were observed in complication rates or pain relief. R-Frey was performed in a selected cohort with more favorable baseline characteristics. After PSM, no significant differences in safety outcomes were detected, although the study was underpowered to establish non-inferiority. The initially observed advantages in hospital stay and ICU stay disappeared after matching, suggesting that they may influenced by patient selection rather than the surgical approach. These findings suggest that R-Frey is partly feasible in carefully selected CP patients, though larger studies are needed to confirm safety equivalence.
- Open Access
- 16 April 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17
New sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: a systematic review and meta-analysis
Background: For resectable pancreatic neuroendocrine tumors (pNETs) located in the body or tail of pancreas that require surgery, distal pancreatectomy with splenectomy (DPS) is standard. While splenic-preserving distal pancreatectomy (SPDP) may reduce complications and provide additional benefits, its feasibility in pNETs remains uncertain. This study compares the perioperative outcomes of SPDP versus DPS for pNET patients. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science included studies published before June 1, 2025. The analysis focused on primary endpoints of intraoperative blood loss (ml) and lymph nodes harvested, as well as secondary endpoints including operative time (min), transfusion, R0 resection, postoperative major complications (PMCs), postoperative pancreatic fistula (POPF), postoperative hemorrhage (PPH), hospital stay (day), lymph node metastasis (LNM), and reintervention. The pooled analysis is presented as odds ratios (OR) or mean differences (MD) with 95% confidence interval (CI). The protocol is registered on PROSPERO (CRD420251079167). Results: 4 retrospective studies involving 457 patients (226 with SPDP and 231 with DPS) were analyzed. 401 patients have well-differentiated G1/G2 tumors, and the majority of SPDP patients have small tumors. Compared to DPS, SPDP had less intraoperative blood loss (SMD, -0.50, 95% CI [-0.90 to -0.11], P = 0.01), fewer lymph nodes examined (MD, -3.30, 95% CI [-5.35 to -1.24], P = 0.002), shorter operative time (MD, -31.78 min, 95% CI [-57.98 to -5.58], P = 0.02), fewer PMCs (OR, 0.57, 95% CI [0.34 to 0.95], P = 0.03) and lower transfusion rates (OR, 0.25, 95% CI [0.07 to 0.83], P = 0.02). In terms of length of hospital stay, SPDP demonstrated more favorable outcomes (MD, −1.13 days, 95% CI [−2.02 to −0.24], P = 0.01). No significant differences were observed regarding R0 resection (OR, 1.40, 95% CI [0.43 to 4.58], P = 0.58), LNM (OR, 0.95, 95% CI [0.49 to 1.85], P = 0.88), or other perioperative outcomes. Conclusion: This study proposes that SPDP may represent a feasible option for selected patients with small, well-differentiated G1/G2 pNETs, suggesting a potential role in reducing surgical risks. These findings should be interpreted as hypothesis-generating, highlighting the need for further investigation. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard , identifier CRD420251079167.
- 16 April 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17
Open AccessNew sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: a systematic review and meta-analysis
Background: For resectable pancreatic neuroendocrine tumors (pNETs) located in the body or tail of pancreas that require surgery, distal pancreatectomy with splenectomy (DPS) is standard. While splenic-preserving distal pancreatectomy (SPDP) may reduce complications and provide additional benefits, its feasibility in pNETs remains uncertain. This study compares the perioperative outcomes of SPDP versus DPS for pNET patients. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science included studies published before June 1, 2025. The analysis focused on primary endpoints of intraoperative blood loss (ml) and lymph nodes harvested, as well as secondary endpoints including operative time (min), transfusion, R0 resection, postoperative major complications (PMCs), postoperative pancreatic fistula (POPF), postoperative hemorrhage (PPH), hospital stay (day), lymph node metastasis (LNM), and reintervention. The pooled analysis is presented as odds ratios (OR) or mean differences (MD) with 95% confidence interval (CI). The protocol is registered on PROSPERO (CRD420251079167). Results: 4 retrospective studies involving 457 patients (226 with SPDP and 231 with DPS) were analyzed. 401 patients have well-differentiated G1/G2 tumors, and the majority of SPDP patients have small tumors. Compared to DPS, SPDP had less intraoperative blood loss (SMD, -0.50, 95% CI [-0.90 to -0.11], P = 0.01), fewer lymph nodes examined (MD, -3.30, 95% CI [-5.35 to -1.24], P = 0.002), shorter operative time (MD, -31.78 min, 95% CI [-57.98 to -5.58], P = 0.02), fewer PMCs (OR, 0.57, 95% CI [0.34 to 0.95], P = 0.03) and lower transfusion rates (OR, 0.25, 95% CI [0.07 to 0.83], P = 0.02). In terms of length of hospital stay, SPDP demonstrated more favorable outcomes (MD, −1.13 days, 95% CI [−2.02 to −0.24], P = 0.01). No significant differences were observed regarding R0 resection (OR, 1.40, 95% CI [0.43 to 4.58], P = 0.58), LNM (OR, 0.95, 95% CI [0.49 to 1.85], P = 0.88), or other perioperative outcomes. Conclusion: This study proposes that SPDP may represent a feasible option for selected patients with small, well-differentiated G1/G2 pNETs, suggesting a potential role in reducing surgical risks. These findings should be interpreted as hypothesis-generating, highlighting the need for further investigation. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard , identifier CRD420251079167.
- Open Access
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744027
Post-pancreatectomy chemotherapy improves the survival of patients with late-stage but not early-stage pancreatic cancer
Background: Although current clinical guidelines recommend that patients who have undergone surgical resection for pancreatic cancer consider adjuvant chemotherapy options, a significant proportion of pancreatic cancer patients undergo surgical resection without receiving adjuvant chemotherapy. One key factor that contributes to this phenomenon is the uncertain effectiveness of adjuvant chemotherapy across various disease stages. The objective of this study was to explore the influence of postoperative chemotherapy on the prognosis of patients with different stages of pancreatic cancer. Methods: We retrospectively analyzed the clinical data of 405 pancreatic cancer patients who underwent pancreatectomy between February 2016 and December 2020 in First Affiliated Hospital of Xi’an Jiaotong University. After excluding patients who did not undergo surgery, received other treatments, or died within 30 days postoperatively, 258 patients were included.96 received adjuvant chemotherapy and 162 did not. Early-stage (stage I, n=59) and late-stage (stages II-IV, n=199) were based on AJCC 8th edition. To minimize intergroup differences, propensity score matching (PSM) was performed. Overall survival (OS) was analyzed using the Kaplan-Meier method and Cox regression analysis. Results: Among the 258 patients, 187 died during follow-up, and the median survival was 14.9 months. Median follow-up was 36.5 months. In the overall cohort, patients receiving chemotherapy had longer median OS than those who did not (17.2 vs 13.3 months; P < 0.001). Chemotherapy significantly improved median survival in late-stage disease (15.6 vs. 11.9 months, P = 0.03), but not in stage I disease (28.0 vs. 27.0 months, P = 0.45). After propensity score matching, multivariable analysis confirmed that chemotherapy was independently associated with improved OS in late-stage disease (HR 0.59; 95% CI 0.38–0.91; P = 0.02). However, no significant survival benefit was observed in stage I patients (HR 0.69; 95% CI 0.27–1.77; P = 0.45). Conclusions: Patients with late-stage pancreatic cancer benefit from adjuvant chemotherapy after pancreatectomy. However, in patients with stage I pancreatic cancer, our data suggest that adjuvant chemotherapy may not confer a significant survival benefit.
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744027
Open AccessPost-pancreatectomy chemotherapy improves the survival of patients with late-stage but not early-stage pancreatic cancer
Background: Although current clinical guidelines recommend that patients who have undergone surgical resection for pancreatic cancer consider adjuvant chemotherapy options, a significant proportion of pancreatic cancer patients undergo surgical resection without receiving adjuvant chemotherapy. One key factor that contributes to this phenomenon is the uncertain effectiveness of adjuvant chemotherapy across various disease stages. The objective of this study was to explore the influence of postoperative chemotherapy on the prognosis of patients with different stages of pancreatic cancer. Methods: We retrospectively analyzed the clinical data of 405 pancreatic cancer patients who underwent pancreatectomy between February 2016 and December 2020 in First Affiliated Hospital of Xi’an Jiaotong University. After excluding patients who did not undergo surgery, received other treatments, or died within 30 days postoperatively, 258 patients were included.96 received adjuvant chemotherapy and 162 did not. Early-stage (stage I, n=59) and late-stage (stages II-IV, n=199) were based on AJCC 8th edition. To minimize intergroup differences, propensity score matching (PSM) was performed. Overall survival (OS) was analyzed using the Kaplan-Meier method and Cox regression analysis. Results: Among the 258 patients, 187 died during follow-up, and the median survival was 14.9 months. Median follow-up was 36.5 months. In the overall cohort, patients receiving chemotherapy had longer median OS than those who did not (17.2 vs 13.3 months; P < 0.001). Chemotherapy significantly improved median survival in late-stage disease (15.6 vs. 11.9 months, P = 0.03), but not in stage I disease (28.0 vs. 27.0 months, P = 0.45). After propensity score matching, multivariable analysis confirmed that chemotherapy was independently associated with improved OS in late-stage disease (HR 0.59; 95% CI 0.38–0.91; P = 0.02). However, no significant survival benefit was observed in stage I patients (HR 0.69; 95% CI 0.27–1.77; P = 0.45). Conclusions: Patients with late-stage pancreatic cancer benefit from adjuvant chemotherapy after pancreatectomy. However, in patients with stage I pancreatic cancer, our data suggest that adjuvant chemotherapy may not confer a significant survival benefit.
- Open Access
Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4‐Mediated Ferroptosis
Pancreatic cancer, one of the most malignant solid tumors with the poorest prognosis, is commonly treated with gemcitabine (GEM)‐based systemic chemotherapy. However, chemoresistance remains a significant therapeutic challenge. Ferroptosis, a novel form of programmed cell death, has demonstrated exceptional susceptibility in chemoresistant cancer cells. Due to their unique magnetic responsiveness, iron oxide nanoparticles can generate heat under alternating magnetic fields, which enables magnetic hyperthermia (MH) therapy. This approach not only directly induces tumor cell apoptosis but also enhances chemosensitization. In this study, we demonstrate that ferrimagnetic vortex‐domain iron oxide nanorings (FVIOs) as an ideal nanoplatform for MH, significantly improving GEM chemosensitivity in pancreatic cancer. Both in vitro and in vivo experiments demonstrated that MH not only synergizes with GEM to exhibit an antitumor effect in wild‐type (WT) pancreatic tumors, but also directly suppresses the proliferation of gemcitabine‐resistant (GR) counterparts while alleviating chemoresistance. High‐throughput transcriptomic profiling revealed an increased susceptibility of GR cells to ferroptosis induction. Mechanistically, MH suppressed HSPB1 expression in GR cells, thereby attenuating its regulatory role in the ubiquitination‐mediated degradation of ACSL4 protein and ultimately promoting ferroptosis. Comprehensive in vivo evaluations confirmed the multidimensional chemosensitizing efficacy of MH alongside favorable biosafety. Our findings highlight MH as a promising adjuvant strategy for pancreatic cancer, particularly in GEM‐resistant cases, by overcoming chemoresistance through the potentiation of ferroptosis.
Open AccessNanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4‐Mediated Ferroptosis
Pancreatic cancer, one of the most malignant solid tumors with the poorest prognosis, is commonly treated with gemcitabine (GEM)‐based systemic chemotherapy. However, chemoresistance remains a significant therapeutic challenge. Ferroptosis, a novel form of programmed cell death, has demonstrated exceptional susceptibility in chemoresistant cancer cells. Due to their unique magnetic responsiveness, iron oxide nanoparticles can generate heat under alternating magnetic fields, which enables magnetic hyperthermia (MH) therapy. This approach not only directly induces tumor cell apoptosis but also enhances chemosensitization. In this study, we demonstrate that ferrimagnetic vortex‐domain iron oxide nanorings (FVIOs) as an ideal nanoplatform for MH, significantly improving GEM chemosensitivity in pancreatic cancer. Both in vitro and in vivo experiments demonstrated that MH not only synergizes with GEM to exhibit an antitumor effect in wild‐type (WT) pancreatic tumors, but also directly suppresses the proliferation of gemcitabine‐resistant (GR) counterparts while alleviating chemoresistance. High‐throughput transcriptomic profiling revealed an increased susceptibility of GR cells to ferroptosis induction. Mechanistically, MH suppressed HSPB1 expression in GR cells, thereby attenuating its regulatory role in the ubiquitination‐mediated degradation of ACSL4 protein and ultimately promoting ferroptosis. Comprehensive in vivo evaluations confirmed the multidimensional chemosensitizing efficacy of MH alongside favorable biosafety. Our findings highlight MH as a promising adjuvant strategy for pancreatic cancer, particularly in GEM‐resistant cases, by overcoming chemoresistance through the potentiation of ferroptosis.
- Open Access
- 25 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1) , 48
Endoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fat-lesion strain ratio, and mean strain histogram for diagnosing pancreatic ductal adenocarcinoma
This study aims to compare three different elastography parameters to evaluate their efficacy in diagnosing Pancreatic Ductal Adenocarcinoma (PDAC) and provide a semi-quantitative or quantitative assessment method for endoscopic ultrasound elastography. We retrospectively analyzed patients with PDAC, patients with benign pancreatic diseases, and individuals with normal pancreas who underwent endoscopic ultrasound elastography at the First Affiliated Hospital of Xi’an Jiaotong University between June 2022 and March 2023. Elastography parameters collected included strain ratio (SR), fat-lesion strain ratio (FLR), and mean strain histogram value (MEAN). Overall, 102 patients were enrolled, comprising 74 patients with PDAC (malignant group), 15 patients with benign lesions, and 13 patients with normal pancreas. Based on the median values, parameters were categorized into different groups for SR, FLR, and MEAN. A significant difference in the distribution between benign and malignant pancreatic lesions was observed across the groups (P < 0.001). ROC curve analysis for diagnosing PDAC across all study subjects showed that when SR > 15.55, FLR > 9.16, and MEAN < 23.85, the lesion area exhibited relatively lower elasticity and greater stiffness, indicating a higher likelihood of PDAC. After excluding normal pancreatic tissue, the study found that when SR > 19.145, FLR > 9.16, and MEAN < 16.25, it was easier to screen for PDAC among patients with pancreatic disease. Further combined analysis of the different parameters revealed that the combined use of the three parameters offered greater advantages in enhancing diagnostic performance. The study reveals that the strain ratio (SR), fat-lesion strain ratio (FLR), and mean strain histogram value (MEAN) are closely related to the characteristics of pancreatic diseases. SR exhibited the highest diagnostic efficacy for PDAC, and combining multiple parameters further improved diagnostic accuracy. Patients with pancreatic disease whose SR > 19.145, FLR > 9.16, and MEAN < 16.25 are more likely to be identified as PDAC.
- 25 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1) , 48
Open AccessEndoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fat-lesion strain ratio, and mean strain histogram for diagnosing pancreatic ductal adenocarcinoma
This study aims to compare three different elastography parameters to evaluate their efficacy in diagnosing Pancreatic Ductal Adenocarcinoma (PDAC) and provide a semi-quantitative or quantitative assessment method for endoscopic ultrasound elastography. We retrospectively analyzed patients with PDAC, patients with benign pancreatic diseases, and individuals with normal pancreas who underwent endoscopic ultrasound elastography at the First Affiliated Hospital of Xi’an Jiaotong University between June 2022 and March 2023. Elastography parameters collected included strain ratio (SR), fat-lesion strain ratio (FLR), and mean strain histogram value (MEAN). Overall, 102 patients were enrolled, comprising 74 patients with PDAC (malignant group), 15 patients with benign lesions, and 13 patients with normal pancreas. Based on the median values, parameters were categorized into different groups for SR, FLR, and MEAN. A significant difference in the distribution between benign and malignant pancreatic lesions was observed across the groups (P < 0.001). ROC curve analysis for diagnosing PDAC across all study subjects showed that when SR > 15.55, FLR > 9.16, and MEAN < 23.85, the lesion area exhibited relatively lower elasticity and greater stiffness, indicating a higher likelihood of PDAC. After excluding normal pancreatic tissue, the study found that when SR > 19.145, FLR > 9.16, and MEAN < 16.25, it was easier to screen for PDAC among patients with pancreatic disease. Further combined analysis of the different parameters revealed that the combined use of the three parameters offered greater advantages in enhancing diagnostic performance. The study reveals that the strain ratio (SR), fat-lesion strain ratio (FLR), and mean strain histogram value (MEAN) are closely related to the characteristics of pancreatic diseases. SR exhibited the highest diagnostic efficacy for PDAC, and combining multiple parameters further improved diagnostic accuracy. Patients with pancreatic disease whose SR > 19.145, FLR > 9.16, and MEAN < 16.25 are more likely to be identified as PDAC.
- Open Access
- 1 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1626664
Risk factors for acute kidney injury in patients with acute pancreatitis and construction of nomogram model: a single-center study and external validation
Objective: This study aims to utilize clinical data from patients with acute pancreatitis (AP) recorded in the MIMIC-IV database to analyze the risk factors associated with acute kidney injury (AKI) and to develop a nomogram prediction model.Methods: This study included clinical data from 754 patients diagnosed with AP sourced from the MIMIC-IV database. They were randomly divided into a training set and an internal validation set. Another 202 patients from the First Affiliated Hospital of Xi’an Jiaotong University were used as an external validation set. Univariate and multivariate logistic regression analyses were conducted to identify the independent influencing factors associated with AKI in these patients. A nomogram model was developed to predict the incidence of AKI, and its performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA).Results: Six independent risk factors were identified as predictors of AKI incidence in patients with AP and utilized to construct the nomogram model. The AUC values for the training set, internal validation set, and external validation set were 0.770 (95% CI, 0.719–0.821), 0.755 (95% CI, 0.676–0.834), and 0.628 (95% CI, 0.551–0.706), respectively. Furthermore, the calibration curve indicates that the predicted outcomes align well with the actual observations. Finally, the DCA demonstrates that the nomogram model possesses significant clinical applicability.Conclusion: The nomogram developed in this study for predicting the incidence of AKI in patients with AP demonstrates strong predictive value and clinical applicability, thereby offering clinicians a more accurate and practical tool for prediction.
- 1 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1626664
Open AccessRisk factors for acute kidney injury in patients with acute pancreatitis and construction of nomogram model: a single-center study and external validation
Objective: This study aims to utilize clinical data from patients with acute pancreatitis (AP) recorded in the MIMIC-IV database to analyze the risk factors associated with acute kidney injury (AKI) and to develop a nomogram prediction model.Methods: This study included clinical data from 754 patients diagnosed with AP sourced from the MIMIC-IV database. They were randomly divided into a training set and an internal validation set. Another 202 patients from the First Affiliated Hospital of Xi’an Jiaotong University were used as an external validation set. Univariate and multivariate logistic regression analyses were conducted to identify the independent influencing factors associated with AKI in these patients. A nomogram model was developed to predict the incidence of AKI, and its performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA).Results: Six independent risk factors were identified as predictors of AKI incidence in patients with AP and utilized to construct the nomogram model. The AUC values for the training set, internal validation set, and external validation set were 0.770 (95% CI, 0.719–0.821), 0.755 (95% CI, 0.676–0.834), and 0.628 (95% CI, 0.551–0.706), respectively. Furthermore, the calibration curve indicates that the predicted outcomes align well with the actual observations. Finally, the DCA demonstrates that the nomogram model possesses significant clinical applicability.Conclusion: The nomogram developed in this study for predicting the incidence of AKI in patients with AP demonstrates strong predictive value and clinical applicability, thereby offering clinicians a more accurate and practical tool for prediction.
- Open Access
- 14 May 2025
- Published by Wolters Kluwer Health in Journal of Pancreatology
Prognostic nomogram for patients with acute pancreatitis complicated with acute kidney injury: a clinical study based on MIMIC-IV database and a college hospital ICU
Purpose: This study aims to analyze the risk factors influencing the survival and prognosis of patients with acute pancreatitis (AP) complicated by acute kidney injury (AKI) and to develop a nomogram model for predicting the overall survival (OS) of these patients. Patients and methods: 616 patients diagnosed with AP sourced from the MIMIC-IV database. They were randomly divided into a training set and an internal validation set. Another 60 patients from the First Affiliated Hospital of Xi’an Jiaotong University were used as an external validation set. Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors affecting the OS of patients. A nomogram model was developed to predict OS, and its performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). Results: Six independent prognostic factors were identified as predictors of OS in patients with AP combined with AKI. These factors were utilized to construct a nomogram model. The AUC values for predicting 1-year, 3-year, and 5-year OS were 0.796, 0.785, and 0.786 in the training set. In the internal and external validation set, the AUC values were 0.828, 0.833, 0.849 and 0.720, 0.810, 0.750, respectively. Furthermore, the calibration curves for several groups showed good consistency, and DCA suggested its clinical usability. Conclusion: The nomogram constructed in this study has a good predictive value, and can be a clinically applicable and practical prediction tool, facilitating rapid and accurate individualized predictions of the patient survival.
- 14 May 2025
- Published by Wolters Kluwer Health in Journal of Pancreatology
Open AccessPrognostic nomogram for patients with acute pancreatitis complicated with acute kidney injury: a clinical study based on MIMIC-IV database and a college hospital ICU
Purpose: This study aims to analyze the risk factors influencing the survival and prognosis of patients with acute pancreatitis (AP) complicated by acute kidney injury (AKI) and to develop a nomogram model for predicting the overall survival (OS) of these patients. Patients and methods: 616 patients diagnosed with AP sourced from the MIMIC-IV database. They were randomly divided into a training set and an internal validation set. Another 60 patients from the First Affiliated Hospital of Xi’an Jiaotong University were used as an external validation set. Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors affecting the OS of patients. A nomogram model was developed to predict OS, and its performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). Results: Six independent prognostic factors were identified as predictors of OS in patients with AP combined with AKI. These factors were utilized to construct a nomogram model. The AUC values for predicting 1-year, 3-year, and 5-year OS were 0.796, 0.785, and 0.786 in the training set. In the internal and external validation set, the AUC values were 0.828, 0.833, 0.849 and 0.720, 0.810, 0.750, respectively. Furthermore, the calibration curves for several groups showed good consistency, and DCA suggested its clinical usability. Conclusion: The nomogram constructed in this study has a good predictive value, and can be a clinically applicable and practical prediction tool, facilitating rapid and accurate individualized predictions of the patient survival.
- Open Access
- 9 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-6
Comparative diagnostic efficacy and safety of ultrasound-guided percutaneous transhepatic biopsy and endoscopic ultrasound-guided fine-needle aspiration biopsy for gallbladder tumors
The objective of this study was to compare the diagnostic efficacy and safety of ultrasound-guided percutaneous transhepatic gallbladder biopsy (PTGB) with endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in the assessment of gallbladder tumors. We conducted a retrospective, single-center study involving 101 patients diagnosed with gallbladder cancer who underwent either PTGB or EUS-FNA between January 2019 and December 2022. The study cohort was divided into two groups: 52 patients underwent PTGB, and 49 underwent EUS-FNA. Clinical data, diagnostic outcomes, patient demographics, and complications were systematically documented. The sensitivity, accuracy, and incidence of complications were evaluated for both groups. The sensitivity and accuracy rates were 94.23% and 94.23% for PTGB compared to 97.82% and 97.96% for EUS-FNA, with no significant difference between the two techniques. However, EUS-FNA was associated with significantly lower rate of adverse reactions (2.04%) compared to PTGB (15.38%). Both PTGB and EUS-FNA exhibited high diagnostic efficacy for gallbladder tumors. However, EUS-FNA demonstrated a significantly lower incidence of complications, making it a compelling alternative to PTGB, especially when percutaneous biopsy is unsuccessful or not feasible. High-quality prospective, multicenter trials are recommended to further validate these findings and to refine biopsy guidelines for gallbladder tumors.
- 9 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-6
Open AccessComparative diagnostic efficacy and safety of ultrasound-guided percutaneous transhepatic biopsy and endoscopic ultrasound-guided fine-needle aspiration biopsy for gallbladder tumors
The objective of this study was to compare the diagnostic efficacy and safety of ultrasound-guided percutaneous transhepatic gallbladder biopsy (PTGB) with endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in the assessment of gallbladder tumors. We conducted a retrospective, single-center study involving 101 patients diagnosed with gallbladder cancer who underwent either PTGB or EUS-FNA between January 2019 and December 2022. The study cohort was divided into two groups: 52 patients underwent PTGB, and 49 underwent EUS-FNA. Clinical data, diagnostic outcomes, patient demographics, and complications were systematically documented. The sensitivity, accuracy, and incidence of complications were evaluated for both groups. The sensitivity and accuracy rates were 94.23% and 94.23% for PTGB compared to 97.82% and 97.96% for EUS-FNA, with no significant difference between the two techniques. However, EUS-FNA was associated with significantly lower rate of adverse reactions (2.04%) compared to PTGB (15.38%). Both PTGB and EUS-FNA exhibited high diagnostic efficacy for gallbladder tumors. However, EUS-FNA demonstrated a significantly lower incidence of complications, making it a compelling alternative to PTGB, especially when percutaneous biopsy is unsuccessful or not feasible. High-quality prospective, multicenter trials are recommended to further validate these findings and to refine biopsy guidelines for gallbladder tumors.